Clinical Case Reports (May 2023)
Hairy cell leukemia with isolated bone lesions
- Laura Cailly,
- Cécile Gruchet,
- Elsa Maitre,
- Stephanie Guidez,
- Vincent Delwail,
- Thomas Systchenko,
- Niels Moya,
- Florence Sabirou,
- Anthony Levy,
- Arthur Bobin,
- Hélène Gardeney,
- Laly Nsiala,
- Mathilde Vonfeld,
- Aurélia Chacon,
- Aurélien Pichon,
- Sabrina Bouyer,
- Caroline Baslé,
- Elodie Dindinnaud,
- Jean‐Claude Chomel,
- Anna Raimbault,
- Florence Borde‐Mougenot,
- Xavier Troussard,
- Cécile Tomowiak
Affiliations
- Laura Cailly
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Cécile Gruchet
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Elsa Maitre
- Department of Hematology, CHU Cote de Nacre University Hospital Caen France
- Stephanie Guidez
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Vincent Delwail
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Thomas Systchenko
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Niels Moya
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Florence Sabirou
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Anthony Levy
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Arthur Bobin
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Hélène Gardeney
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Laly Nsiala
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Mathilde Vonfeld
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Aurélia Chacon
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Aurélien Pichon
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- Sabrina Bouyer
- Department of Biology, CHU La Miletrie University Hospital Poitiers France
- Caroline Baslé
- Department of Biology, CHU La Miletrie University Hospital Poitiers France
- Elodie Dindinnaud
- Department of Biology, CHU La Miletrie University Hospital Poitiers France
- Jean‐Claude Chomel
- Department of Biology, CHU La Miletrie University Hospital Poitiers France
- Anna Raimbault
- Department of Biology, CHU La Miletrie University Hospital Poitiers France
- Florence Borde‐Mougenot
- Department of Oncology, CH Saintes Saintes France
- Xavier Troussard
- Department of Hematology, CHU Cote de Nacre University Hospital Caen France
- Cécile Tomowiak
- Department of Hematology and Cellular Therapy, and INSERM CIC1402 CHU La Miletrie, University Hospital Poitiers France
- DOI
- https://doi.org/10.1002/ccr3.7343
- Journal volume & issue
-
Vol. 11,
no. 5
pp. n/a – n/a
Abstract
Key Clinical Message 18F‐FDG PET/CT has clinical relevance in HCL at diagnosis and for the follow‐up of patients treated, especially in case of atypical presentations such as bone involvements (which are probably underestimated) and poor bone marrow infiltration. Abstract Bone lesions are rarely reported in Hairy Cell Leukemia (HCL). We report two BRAFV600E mutated HCL patients presented bone lesions at foreground, poor bone marrow involvement, and the important role 18F‐FDG PET/CT played in their management. We discuss the crucial role that 18F‐FDG PET/CT could play in HCL routine practice.
Keywords
